FUROSEMIDE (furosemide) by Hikma. Approved for loop diuretic [epc]. First approved in 1983.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
Furosemide is a generic loop diuretic oral tablet approved in 1983 that works by inhibiting sodium and chloride reabsorption in the ascending loop of Henle. It is indicated for the management of edema associated with congestive heart failure, liver cirrhosis, and renal disease, as well as for hypertension. The drug remains a foundational therapy for fluid overload management across multiple therapeutic areas.
As a mature generic with LOE approaching, this product likely operates with lean teams focused on cost management and market share defense rather than growth initiatives.
Loop Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bumetanide vs. Furosemide in Cirrhosis
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
Study to Compare Bioavailability and Pharmacokinetics of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80 mg) Administered Intravenously in Healthy Volunteers
A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
Worked on FUROSEMIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moFurosemide offers limited career growth potential due to its mature generic status and approaching loss of exclusivity; roles are concentrated in operations, manufacturing, and regulatory compliance rather than commercial expansion or innovation. Career progression on this product typically leads toward supply chain, quality, or manufacturing expertise rather than brand leadership.